OTX-TKI (Axpaxli) offers a novel approach for wet macular degeneration with sustained drug release up to 9 months via a hydrogel platform. Two phase 3 trials, SOL-1 and SOL-R, evaluate Axpaxli's ...

Are you itching to catch presentations from the Ophthalmology Times® editorial advisory board? Twenty of our esteemed clinical advisors will be showcasing their work during the American Academy of ...

The EURETINA meeting attracted over 11,000 attendees, showcasing advancements in retinal disease treatments, including gene therapy and implants for geographic atrophy. Gene therapy offers a potential ...

MK-3000, a tri-specific antibody, is being tested in the BRUNELLO trial for diabetic macular edema, following positive AMARONE trial results.

The US Food and Drug Administration (FDA) has granted Nacuity Pharmaceuticals’ N-acetylcysteine amide tablets (NPI-001) breakthrough therapy designation.

AAVB-039 targets Stargardt disease by delivering the full-length ABCA4 protein, addressing the genetic cause of the condition. The FDA granted Orphan Drug and Fast Track Designations, while the UK's ...

A new British study reported that treatment with intravitreal complement inhibitors (IVCIs) for geographic atrophy (GA) was viewed favorably by patients if the treatment was thought to impart visual ...

ANX007 targets C1q to inhibit the complement cascade, reducing neuroinflammation and protecting photoreceptors in AMD and GA. The ARCHER trial showed significant vision loss reduction, with a 73% risk ...

VIZZ, an aceclidine-based eye drop, is now available for presbyopia treatment, following FDA approval, with distribution to optometrists and ophthalmologists underway. The solution enhances near ...

A panelist discusses how an 83-year-old patient with diabetic macular edema (DME) who showed suboptimal response to standard anti-VEGF therapies, including aflibercept 2 mg and faricimab, ultimately ...

The ACTOR study finds OCT angiography cannot predict exudative recurrence in neovascular AMD but offers valuable vascular remodeling insights. The HERMES study reveals worsening peripheral ...

Lupin’s subsidiary, Nanomi, has signed a definitive agreement to acquire VISUfarma, a portfolio company of GHO Capital Partners LLP. Lupin notes that the acquisition will help the company expand its ...